Iodinated activated charcoal - PharmaLundensis

Drug Profile

Iodinated activated charcoal - PharmaLundensis

Alternative Names: IodoCarb; Jodkol

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator PharmaLundensis
  • Class Absorbents
  • Mechanism of Action Binding agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic fatigue syndrome; Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Feb 2016 No development reported - Phase-II for Chronic obstructive pulmonary disease in Sweden (PO)
  • 17 Feb 2016 No development reported - Phase-I/II for Chronic fatigue syndrome in Sweden (PO)
  • 31 May 2013 PharmaLundensis completes a phase II trial in Chronic obstructive pulmonary disease in Sweden (NCT01404000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top